SLU-PP-322 research and evidence overview

The entire evidence base here is preclinical, and it is small: one line of work from a single academic laboratory, in mice, published in 2024. There are no human trials, no published human pharmacokinetics, no toxicology package in the public record, and no regulatory filing. Every claim about fat loss, endurance, or "exercise in a bottle" traces back to diet-induced-obese and ob/ob mice given the compound by injection.

The compound described in the peer-reviewed literature is SLU-PP-332, not SLU-PP-322 — a synthetic small molecule agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ, developed in Thomas Burris's laboratory. It is not a peptide at all. Product listings using the transposed digits are common, and they are worth flagging, because a search on the marketed name returns almost nothing from the scientific record while the correct name returns the actual pharmacology.

ERRs are orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and the transcriptional programme that skeletal muscle runs during endurance exercise. That is the mechanistic basis for calling an ERR agonist an exercise mimetic.

Billon and colleagues, A Synthetic ERR Agonist Alleviates Metabolic Syndrome (Journal of Pharmacology and Experimental Therapeutics, 2024), administered SLU-PP-332 to diet-induced obese mice and to ob/ob mice. The reported effects were increased whole-body energy expenditure and fatty acid oxidation, decreased fat mass accumulation, reduced obesity, and improved insulin sensitivity — a profile the authors describe as mimicking the metabolic benefits of acute aerobic exercise.

Read carefully, the paper is a proof-of-concept for a drug target. Its own significance statement frames ERR agonism as something that "holds promise as a therapeutic," which is the standard language for a compound that has not entered clinical development.

None exists in the published literature. No completed or recruiting human trial of SLU-PP-332 is described in the peer-reviewed record, which means there is no information on:

• Whether the mouse dose translates to any tolerable human dose.
• Oral bioavailability and half-life in people — the mouse work used injection, and short half-life has been an acknowledged constraint on this chemical series.
• Off-target effects of activating a nuclear receptor family expressed in heart, liver, bone, and brain, not only muscle.
• Any safety signal at all beyond short rodent dosing.

Rodent metabolic models are notoriously generous. Compounds that reduce fat mass and improve insulin sensitivity in diet-induced obese mice have failed in humans often enough that the field treats such results as a starting point, not a prediction. The gap here is also unusually wide: a nuclear receptor agonist acting on a transcriptional programme is the kind of drug whose long-term effects — on cardiac tissue, on cell proliferation — only surface in extended studies that have not been run. Material sold under this name is research chemical supply, unapproved for human use in any jurisdiction, and purity is unverified by any regulator.